🔴🔴Our paper is out today in @CellCellPress! Since the preprint and thanks to the reviewers, we added a validation series of 10,000+ patients, an analysis of the timing of metastases & linked different analyses to further extended the hypotheses

RT @FAndreMD: Tks anirban !.RNA seq and whole exome in 1000 and 500 pretreated metastatic cancers. Interesting to see the impact of prior t….

RT @MSKLibrary: Featured today by @MSKLibrary: Outcomes and Molecular Features of Brain Metastasis in. @bastien_ng….

RT @chatila_w: Our latest manuscript studying rectal cancer is out in @NatureMedicine. This is work led by @DrGarciaAguilar, @fsanchezvega….

RT @Goutam_Chak: PIK3R1-mutation regulates Insulin-PI3K-glycolytic pathway in #prostatecancer. Our @CCR_AACR paper shows frequent oncogenic….

RT @BarbMarte: new out in Nature, wonderful paper exploring the events in the first next cell cycle after whole genome duplication:.https:/….

RT @jakelee0711: What a striking finding on questionable driver -- KRAS Q61K mutation. It seems like this is functional only when this coex….

RT @jgoecks: Our new @NCIHTAN paper has been published! It presents a unique spatial atlas of linked multimodal datasets from serial biopsi….

RT @CDebyaniPhD: @ASCO Provisional Clinical Opinion re Somatic Genomic Testing in pts w/ Metastatic or Adv Cancer is out!. An honor to be o….

RT @Cancer_Cell: Online Now: Metastasis and organotropism: A look through the lens of large-scale clinical sequencing data .

RT @CD_AACR: Read this week's Cancer Discovery #ResearchWatch Genomic Alterations Distinguish Patterns of Metastatic Dissemination by @niko….

I can’t imagine a better way to wrap up my postdoc! Beyond grateful to @sloan_kettering, @nikolausschultz @fsanchezvega, @CJFongPhD, and many others for those exciting years 🙏.

The clinical and genomic data are publicly available today, including detailed timelines of metastatic events in individual patient views. Kudos to the @cbioportal team 💪! .

RT @sloan_kettering: 🚨 Breaking - Data from 25,000 patients is helping scientists at MSK's Sloan Kettering Institute answer — can a tumor's….

RT @NatRevClinOncol: In a phase II study of the KIT inhibitor imatinib plus the MEK inhibitor binimetinib as first-line therapy for advance….

RT @VivekSubbiah: KIT+ MEK inhibition in GIST ➡️Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastr….

RT @chaiband: Proud to share our work out today in @NatureGenet. With @srinipr4, @MFBerger1 and @BarryTaylorLab. .

RT @DrPhilKantoff: Black men die from prostate cancer twice as often as White men. @BrandonMahal, @FranklinHuang, @KOSJ12, and others have….

RT @CDebyaniPhD: @OncoKB's @US_FDA tab is @FDAOncology recognized! A 3y journey & we couldn't be prouder to state we are the 1st somatic tu….

RT @EdReznik: Perhaps the best and most caring cancer genomics mentor in the world to work with 👇.